Residency · Residency · Medical Genetics Genomics
Osteogenesis Imperfecta: Spectrum, Diagnosis, and Emerging Therapies
Introduction
Osteogenesis imperfecta (OI) is a heritable skeletal disorder primarily caused by defects in type I collagen synthesis, structure, or processing. Characterized by bone fragility and recurrent fractures, OI encompasses a broad clinical spectrum from mild disease with near-normal stature to perinatally lethal forms. Advances in molecular genetics have expanded the classification well beyond the original Sillence types.
Classification and Clinical Spectrum
Classic Sillence Classification
Type I (mild) is the most common form and results from a quantitative collagen defect. Patients have normal or near-normal stature, blue sclerae, relatively few fractures, and minimal deformity. Type II (perinatal lethal) is the most severe, presenting with crumpled long bones, beaded ribs, severe undermineralization, and death in utero or within weeks of birth. Type III (progressively deforming) is severe, with progressive skeletal deformity, very short stature, triangular facies, and frequently dentinogenesis imperfecta. Type IV (moderate) has variable severity with normal or gray sclerae, moderate short stature, and variable deformity.
| OI Type | Severity | Sclerae | Stature | Collagen Defect | Inheritance | Key Features |
|---|---|---|---|---|---|---|
| I | Mild | Blue | Normal/near-normal | Quantitative (reduced amount) | AD (COL1A1 null) | Few fractures; minimal deformity |
| II | Perinatal lethal | Blue/dark | Severe shortening | Qualitative (structural) | AD (de novo) or AR | Crumpled bones; beaded ribs; lethal |
| III | Severe/progressive | Variable | Very short | Qualitative (structural) | AD or AR | Progressive deformity; DI common; triangular facies |
| IV | Moderate | Normal/gray | Moderate short stature | Qualitative (structural) | AD | Variable deformity; DI in some |
| V | Moderate | Normal | Variable | IFITM5 c.-14C>T | AD | Hyperplastic callus; interosseous membrane calcification |
Expanded Genetic Classification
Types V through XX have been described based on distinct molecular etiologies. Type V results from an IFITM5 variant (c.-14C>T) and features hyperplastic callus formation, calcification of the interosseous membrane, and a mesh-like lamellar bone pattern. Autosomal recessive forms involve genes critical to collagen modification and folding, including CRTAP, LEPRE1/P3H1, and PPIB (the prolyl 3-hydroxylation complex), SERPINH1 (the collagen chaperone HSP47), FKBP10 (peptidyl-prolyl isomerase), BMP1 (C-propeptide cleavage), and WNT1 (Wnt signaling pathway, also associated with early-onset osteoporosis). More recently identified genes include SPARC, MBTPS2, TENT5A, and MESD.
Molecular Pathophysiology
Type I Collagen Biology
Type I collagen is a heterotrimer composed of two alpha-1 chains (encoded by COL1A1) and one alpha-2 chain (encoded by COL1A2). These chains form a triple helix with a repeating Gly-X-Y motif, and glycine substitutions disrupt helix stability. Quantitative defects, typically from COL1A1 null alleles, result in reduced but structurally normal collagen and generally produce mild OI (Type I). Qualitative defects from missense variants, especially glycine substitutions, produce structurally abnormal collagen with dominant-negative effects, and severity correlates with position within the chain and the substituting amino acid.
Genotype-Phenotype Correlations
Glycine substitutions closer to the C-terminus tend to be more severe due to the C-to-N direction of helix folding. Substitutions to charged or bulky residues (Asp, Glu, Arg) are typically more severe than substitutions to Ser or Ala. COL1A1 glycine substitutions are generally more severe than equivalent COL1A2 substitutions. Exon-skipping variants in COL1A1 or COL1A2 produce variable phenotypes depending on the region affected.
Diagnostic Approach
Clinical Assessment
Key findings include a fracture history disproportionate to trauma (particularly in the first years of life), blue or gray sclerae (though not specific, as they are present in normal infants), dentinogenesis imperfecta (opalescent, discolored teeth with enamel chipping), hearing loss (mixed or sensorineural, typically developing in the second to fourth decades), short stature (absent in Type I, variable to severe in other types), and Wormian bones (intrasutural bones) on skull radiographs. A skeletal survey documents fracture pattern and bone deformity.
Molecular and Biochemical Testing
Gene panel testing including COL1A1, COL1A2, and recessive OI genes is first-line. Collagen biochemistry from dermal fibroblast culture using gel electrophoresis can identify qualitative defects but is being supplanted by molecular testing. Prenatal diagnosis via ultrasound may detect severe forms in the second trimester, with confirmatory molecular testing via CVS or amniocentesis.
Differential Diagnosis
Non-accidental injury (child abuse) is a critical differential; OI should be considered in any child with unexplained fractures, and genetic testing can help resolve the distinction. Idiopathic juvenile osteoporosis is self-limited with no collagen defect. Hypophosphatasia presents with low alkaline phosphatase from ALPL variants. Other skeletal fragility disorders include Bruck syndrome and osteoporosis-pseudoglioma syndrome.
Current Standard-of-Care Therapies
Bisphosphonates (pamidronate IV, zoledronic acid) increase bone mineral density, decrease fracture rate (primarily vertebral), and reduce bone pain, representing the standard of care for moderate-to-severe OI. Orthopedic management includes intramedullary rodding (telescoping rods for growing children), fracture fixation, and scoliosis management. Physical therapy and rehabilitation maximize function, prevent deconditioning, and incorporate aquatic therapy. Dental care includes crowns and protective measures for dentinogenesis imperfecta. Regular hearing assessments beginning in adolescence are recommended.
Emerging and Investigational Therapies
Anti-RANKL therapy (denosumab) is a potent antiresorptive used off-label in pediatric OI, with caution regarding rebound hypercalcemia upon discontinuation. Anti-sclerostin antibodies (romosozumab) represent an anabolic bone agent with clinical trials in OI underway. TGF-beta pathway modulation (fresolimumab) targets excessive TGF-beta signaling in OI bone. Cell-based therapies using mesenchymal stem cell transplantation (prenatal and postnatal) have shown feasibility in early clinical trials. Gene therapy approaches include allele-specific silencing using siRNA or antisense oligonucleotides to suppress the dominant-negative allele. CRISPR-based strategies in preclinical studies target mutant COL1A1 alleles, with base editing approaches to correct glycine substitutions.
Clinical Pearls
A quantitative collagen defect (haploinsufficiency) generally produces milder disease than a qualitative (dominant-negative) defect. The distinction between OI and non-accidental injury requires careful clinical, radiographic, and often genetic evaluation; importantly, these diagnoses are not mutually exclusive. Bisphosphonates improve bone density and reduce vertebral fractures but do not normalize collagen quality, and long bone fracture reduction is less robust. Autosomal recessive OI should be considered when parents are consanguineous or when the phenotype is severe but collagen genes are normal on sequencing.
References
- Marini JC, Forlino A, Bachinger HP, et al. Osteogenesis imperfecta. Nature Reviews Disease Primers. 2017;3:17052.
- Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. Journal of Medical Genetics. 1979;16(2):101-116.
- Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database of Systematic Reviews. 2016;10:CD005088.
- Hoyer-Kuhn H, Netzer C, Koerber F, et al. Two years' experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet Journal of Rare Diseases. 2019;14:60.